Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222286 · ClinicalTrials.gov registry record · Phase 2
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
A Phase 2 study of Smoldering Multiple Myeloma, sponsored by Innate Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT01222286 is a Phase 2 study of Smoldering Multiple Myeloma that has completed, run by Innate Pharma. The registered enrollment target is 30 participants, below the 798-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01222286, a Phase 2 study of Smoldering Multiple Myeloma, has completed, sponsored by Innate Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
Conditions Studied
Interventions
- DRUG IPH2101
Study Locations (5)
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Mount Sinai School of Medicine - New York
Ohio
- Ohio State University - Columbus
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01222286
The ClinicalTrials.gov registry entry for NCT01222286 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 798-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (96% lower). The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which IPH2101 is the first listed.
NCT01222286 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT01222286 about?
NCT01222286 is a clinical study titled "Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma". The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
What is the current status of trial NCT01222286?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2010-09. Estimated completion is 2013-01.
What conditions does trial NCT01222286 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma.
What interventions are being tested in trial NCT01222286?
The interventions under investigation include: IPH2101 (DRUG).
Who is sponsoring clinical trial NCT01222286?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01222286 being conducted?
This trial has 5 study locations across Massachusetts, New York, Ohio, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
ACTIVE NOT RECRUITING · Phase 2
-
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.